To date, the V2R antagonist tolvaptan has provided clinical benefits in patients with heart failure, SIADH, and ADPKD by inhibiting intracellular cAMP production in the kidney1–4. The gene discussed is AVPR2; the disease is autosomal dominant polycystic kidney disease.